Het longmicrobioom

Het oude paradigma van de 19e - 20e eeuw beschouwde de mens als een 'zelfvoorzienend organisme' en alle microben als vijanden die uitgeroeid moeten worden om ziekte te genezen. Recente wetenschappelijke inzichten hebben de onjuistheid hiervan aangetoond en liggen aan de basis het nieuwe en correctere concept van de mens als 'supra-organisme': een symbiose met microbiële gemeenschappen als partners, waarbij een delicate balans de grens tussen gezondheid en ziekte bepaalt.

Beste bezoeker, u heeft geen toegang.

Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.

U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!

Auteur

Marleen Nys

Trefwoorden:

Figuren

Verschenen in

Referenties

  1. Blaser MJ. The microbiome revolution. J Clin Invest. 2014 Oct 1;124(10):4162-5.

  2. Ottman N, Smidt H, de Vos WM, Belzer C. The function of our microbiota: who is out there and what do they do? Front Cell Infect Microbiol. 2012 Aug 9;2:104.

  3. NIH HMP Working Group, Peterson J, Garges S, et al. The NIH Human Microbiome Project. Genome Res 2009;19:2317-23.

  4. http://www.mynewgut.eu

  5. Raes J. Intestinal flora determines health of obese people. ScienceDaily. ScienceDaily, 28 August 2013. www.sciencedaily.com/releases/2013/08/130828131932.htm.

  6. Nieuwdorp M. Fecal transplantation in obesity/type 2 diabetes. Endocrine Abstracts (2014) 35 S12.2 

  7. Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol 2009;7:887-94.

  8. Hui AWH, Lau HW, Chan THT, Tsui SKW. The human microbiota: a new direction in the investigation of thoracic diseases. J Thorac Dis 2013; 5(S2):S127-31

  9. Redinbo MR. The Microbiota, Chemical Symbiosis, and Human Disease. J Mol Biol. 2014 Oct 8. pii: S0022-2836(14)00498-7.

  10. Segal LN, Blaser MJ. A brave new world: the lung microbiota in an era of change. Ann Am Thorac Soc. 2014;11(S1):S21-7.

  11. Hui AW et al. The human microbiota: a new direction in the investigation of thoracic diseases. J Thorac Dis 2013 Aug;5 Suppl 2:S127-31.

  12. Kiley JP, Caler EV. The Lung Microbiome. A New Frontier in Pulmonary Medicine", Annals Am Thoracic Soc 2014; 11(S1):S66-S70.

  13. Beck JM, Young VB, Huffnagle GB. The microbiome of the lung. Transl Res 2012;160(4):258-66.

  14. Cui L et al. The microbiome and the lung. Ann Am Thorac Soc. 2014; 11(S4):S227-32.

  15. Huang YJ et al. The role of the lung microbiome in health and disease. A National Heart, Lung, and Blood Institute workshop report. Am J Respir Crit Care Med.;187(12):1382-7

  16. Garcia-Núñez M, Setó L, et al. Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease. J Clin Microbiol 2012;50:3562-8.

  17. Sze MA, Hogg JC, Sin DD. Bacterial microbiome of lungs in COPD. Int J Chron Obstruct Pulmon Dis. 2014 Feb 21;9:229-38.

  18. Sze MA et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 May 15;185(10):1073-80.

  19. Pragman AA, Kim HB, Reilly CS, et al. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One 2012;7:e47305.

  20. Surette MG. The cystic fibrosis lung microbiome. Ann Am Thorac Soc. 2014;11(S1):S61-5.

  21. Dickson RP et al. The role of the microbiome in exacerbations of chronic lung diseases. Lancet 2014 Aug 23;384(9944):691-702.

  22. Huang YJ, Lynch SV. The emerging relationship between the airway microbiota and chronic respiratory disease: clinical implications. Expert Rev Respir Med. Dec 2011; 5(6): 809–821.

  23. Dickson RP et al. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir Med. 2014 Mar;2(3):238-46.

  24. Gollwitzer ES, Marsland BJ. Microbiota abnormalities in inflammatory airway diseases - Potential for therapy. Pharmacol Ther. 2014;141(1):32-9.

  25. Segal LN et al. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. Microbiome 2013 Jul 1;1(1):19.

  26. Kolwijck E, van de veerdonck FL. The potential impact of the pulmonary microbiome on immunopathogenesis of Aspergillus-related lung disease. Eur J Immunol. 2014 Sep 25. doi: 10.1002/eji.201344404. [Epub ahead of print]

  27. Gollwitzer ES, Marsland BJ. Microbiota abnormalities in inflammatory airway diseases - Potential for therapy. Pharmacol Ther. 2014 Jan;141(1):32-9.

  28. Han MK, Huang YJ, Lipuma JJ, et al. Significance of the microbiome in obstructive lung disease. Thorax 2012;67:456-63.

  29. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One 2011;6:e16384.

  30. Morris A, Beck JM, Schloss PD, et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med 2013;187:1067-75.

  31. Cabrera-Rubio R, Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011;184:957-63.

  32. Dickson RP et al. Cell-associated bacteria in the human lung microbiome. Microbiome. 2014; 18;2:28.

  33. Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol 2009;7:887-94.

  34. Wang H. Gut-lung crosstalk in pulmonary involvement with inflammatory bowel diseases. World J Gastroenterol. 2013 Oct 28;19(40):6794-804.

  35. Ateş F, Karincaoğlu M, Hacievlıyagıl SS, Yalniz M, Seçkın Y. Alterations in the pulmonary function tests of inflammatory bowel diseases. Turk J Gastroenterol. 2011 Jun;22(3):293-9.

  36. Segal LN, Rom WN, Weiden MD. Lung microbiome for clinicians. New discoveries about bugs in healthy and diseased lungs. Ann Am Thorac Soc. 2014 Jan;11(1):108-16.

  37. Beck JM. ABCs of the lung microbiome. Ann Am Thorac Soc. 2014 Jan;11 Suppl 1:S3-6.

  38. Wang J et al. Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation. J Exp Med. 2014 Nov 3. pii: jem.20140625. [Epub ahead of print]

  39. Ichinohe T et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci USA 2011 Mar 29;108(13):5354-9.

  40. Wu S et al. Microbiota regulates the TLR7 signaling pathway against respiratory tract influenza A virus infection. Curr Microbiol 2013 Oct;67(4):414-22.

  41. Ichinohe T, Pang IK, Kumamoto Y, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci U S A 2011;108:5354-9.

  42. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008;198:962-70.

  43. Martinez FD. The human microbiome. Early life determinant of health outcomes. Ann Am Thorac Soc. 2014 Jan;11 Suppl 1:S7-12.

  44. Martin TR, Frevert CW. Innate immunity in the lungs. Proc Am Thorac Soc. 2005;2(5):403-11.

  45. Marsland BJ. Influences of the microbiome on the early origins of allergic asthma. Ann Am Thorac Soc 2013;10 Suppl:S165-9.

  46. Gaffin JM et al. Perinatal and early childhood environmental factors influencing allergic asthma immunopathogenesis. Int Immunopharmacol. 2014 Sep;22(1):21-30.

  47. Kim TH, Lee HK. Innate immune recognition of respiratory syncytial virus infection. BMB Rep 2014 Apr;47(4):184-91.

  48. Holgate ST. The sentinel role of the airway epithelium in asthma pathogenesis. Immunol Rev. 2011 Jul;242(1):205-19.

  49. Proud D, Leigh R. Epithelial cells and airway diseases. Immunol Rev. 2011 Jul;242(1):186-204.

  50. Davidson S et al. Plasmacytoid dendritic cells promote host defense against acute pneumovirus infection via the TLR7-MyD88-dependent signaling pathway. J Immunol 2011 May 15;186(10):5938-48.

  51. Kaiko GE et al. Toll-like receptor 7 gene deficiency and early-life Pneumovirus infection interact to predispose toward the development of asthma-like pathology in mice. J Allergy Clin Immunol. 2013 May;131(5):1331-9.e10

  52. Daley D. The evolution of the hygiene hypothesis: the role of early-life exposures to viruses and microbes and their relationship to asthma and allergic diseases. Curr Opin Allergy Clin Immunol. 2014 Oct;14(5):390-6

  53. Huang YJ, Boushey HA. The microbiome and asthma. Ann Am Thorac Soc. 2014 Jan;11 Suppl 1:S48-51.

  54. Clarke TB. Early Innate Immunity to Bacterial Infection in the Lung Is Regulated Systemically by the Commensal Microbiota via Nod-Like Receptor Ligands. Infect Immun. 2014 Nov;82(11):4596-606.

  55. Wills-Karp M1, Santeliz J, Karp CL. The immunological basis of the hygiene hypothesis. Chem Immunol Allergy. 2006;91:30-48.

  56. http://www.europeanlung.org/en/news-and-events/media-centre/press-releases 08/09/2014

  57. Vael C et al. Early intestinal Bacteroides fragilis colonisation and development of asthma. BMC Pulm Med 2008 Sep 26;8:

  58. Zhao J, Murray S, Lipuma JJ. Modeling the impact of antibiotic exposure on human microbiota. Sci Rep. 2014 Mar 11;4:4345.

  59. Bou Saab J, Losa D, Chanson M, Ruez R. Connexins in respiratory and gastrointestinal mucosal immunity. FEBS Lett 2014; 17;588(8):1288-96.

  60. Randall TD. Bronchus-associated lymphoid tissue (BALT) structure and function. Adv Immunol 2010;107:187-241.

  61. Kawamata N et al. Expression of endothelia and lymphocyte adhesion molecules in bronchus-associated lymphoid tissue (BALT) in adult human lung. Respir Res 2009 Oct 22;10:97.

  62. Bou Saab J, Losa D, Chanson M, Ruez R. Connexins in respiratory and gastrointestinal mucosal immunity. FEBS Lett 2014; 17;588(8):1288-96.

  63. Heier I et al. Characterisation of bronchus-associated lymphoid tissue and antigen-presenting cells in central airway mucosa of children. Thorax 2011 Feb;66(2):151-6.

  64. Weng M, Walker WA. The role of gut microbiota in programming the immune phenotype. J Dev Orig Health Dis. 2013 Jun;4(3):203-14.

  65. Lu DG, Ji XQ, Liu X, Li HJ, Zhang CQ. Pulmonary manifestations of Crohn's disease. World J Gastroenterol. 2014 Jan 7;20(1):133-41.

  66. Wang H, Liu JS, Peng SH, Deng XY, Zhu DM, Javidiparsijani S, Wang GR, Li DQ, Li LX, Wang YC, Luo JM. Gut-lung crosstalk in pulmonary involvement with inflammatory bowel diseases. World J Gastroenterol. 2013 Oct 28;19(40):6794-804.

  67. Cross ML. Immune-signalling by orally-delivered probiotic bacteria: effects on common mucosal immunoresponses and protection at distal mucosal sites. Int J Immunopathol Pharmacol. 2004 May-Aug;17(2):127-34.

  68. Alexandre Y, Le Blay G, Boisramé-Gastrin S, Le Gall F, Héry-Arnaud G, Gouriou S, Vallet S, Le Berre R. Probiotics: a new way to fight bacterial pulmonary infections? Med Mal Infect. 2014 Jan;44(1):9-17.

  69. Mortaz E, Adcock IM, Folkerts G, Barnes PJ, Paul Vos A, Garssen J. Probiotics in the management of lung diseases. Mediators Inflamm. 2013;2013:751068.

Nog interessante lectuur:

  1. Jasti C et al. How Do Small Things Make a Big Difference? Activities to Teach about Human–Microbe Interactions. The American Biology Teacher 2014 Nov-Dec; 76(9 ):601-608.

  2. Blaser MJ. Missing Microbes: ISBN-13: 978-0805098105 ISBN-10: 0805098100

  1. The microbe discoveryproject van Prof. Ian Lipkin: onderzoek naar het verband tussen CVS-ME en het darmmicrobioom http://www.microbediscovery.org/nl/

Gerelateerde artikelen

Leververvetting: een sluimerende aandoening met ernstige gevolgen
Biofilm in de darm behandelen
Een nieuw behandelingsmodel voor niet-infectieuze ziekten
Zink nuttig bij prostatitis
Huidmicrobioom sleutelfactor bij kraaienpootjes?